Exane Derivatives Atea Pharmaceuticals, Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Exane Derivatives holds 78 shares of AVIR stock, worth $301. This represents 0.0% of its overall portfolio holdings.
Number of Shares
78
Previous 78
-0.0%
Holding current value
$301
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AVIR
# of Institutions
111Shares Held
51.2MCall Options Held
71.8KPut Options Held
318K-
Black Rock Inc. New York, NY9.12MShares$35.3 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN6.38MShares$24.7 Million15.06% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.44MShares$21.1 Million0.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.72MShares$18.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.48MShares$17.3 Million1.81% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $322M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...